Ann: Investor Presentation - $66m Capital Raise, page-64

@avarive09

So you've read up hey?

LNA043 is an unproven protein therapy that has P2 clinical trials set to run for 5 years (late 2027)

Whilst admirable, cartilage repair via still unknown MOA has many additional hurdles to overcome. Moreover, it's really only attacking one piece of the OA puzzle.

Remember PAR's Zilosul only needs 10% US OA market traction to get to CSL annual revenue. So plenty of room for competition when and if it arrives.

I terms of much bigger company and resources comment. All the top 15 biopharma groups by revenue all sponsor specific OA research. Wonder which ones PAR is currently talking to is perhaps the more pertinent question??????